Skip to content

Bausch + Lomb BLCO Other accrued liabilities

Other accrued liabilities at other companies

Warby Parker logo
Warby ParkerWRBY
Solventum logo
SolventumSOLV
PBH
Prestige Consumer HealthcarePBH
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
Viatris logo
ViatrisVTRS
Kenvue logo
KenvueKVUE

Other financials

Income statement

See full
Revenue$1.2B+9.4%
Operating income$33.0M+140%
Net income-$71.0M+66.5%
EPS (diluted)-$0.20+66.7%

Balance sheet

See full
Cash & equivalents$279.0M+29.8%
Total debt$5.0B+4.3%
Total equity$6.4B+0.3%
Total assets$13.8B+2.6%

Cash flow

See full
Operating cash flow$32.0M+228%
CapEx$100.0M-9.1%
Free cash flow-$68.0M+49.6%

Valuation

See full
Market cap$5.43B+10.2%

Profitability

See full
Operating margin4.4%+2.9pp
Net margin-4.2%-1.3pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-3.4%-0.9pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.

The official record: Bausch + Lomb’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch + Lomb's other accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bausch + Lomb's other accrued liabilities?
Bausch + Lomb (BLCO) reported other accrued liabilities of $560M in Q1 2026.
How has Bausch + Lomb's other accrued liabilities changed year-over-year?
Bausch + Lomb's other accrued liabilities increased by 78.9% year-over-year, from $313M to $560M.
What is the long-term trend for Bausch + Lomb's other accrued liabilities?
Over 4 years (2021 to 2025), Bausch + Lomb's other accrued liabilities has grown at a 14.9% compound annual growth rate (CAGR), from $316M to $551M.